Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsed or refractory CLL.~* Experiencing progressive disease with an iwCLL-WG indication to receive therapy.~* Age ≥ 18 years.~* ECOG performance status ≤ 2 at study entry.~* Adequate organ and marrow function as defined below:~* platelets ≥ 50 x 109/L~* serum creatinine ≤ 1.5 mg/dL~* total bilirubin ≤ 1.5 mg/dL~* AST(SGOT)/ALT(SPGT) ≤ 2 X institutional upper limit of normal or if known liver involvement \<5X institutional upper limit of normal~* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~* Ability to understand and the willingness to sign a written informed consent.~Exclusion Criteria:~* No investigational agents within 28 days prior to entering the study.~* No concurrent use of other anti-cancer agents or treatments.~* No congestive heart failure \> class II NYHA. Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (beginning within the last 3 months) or myocardial infarction within the past 6 months.~* No known brain metastases (progressive neurologic dysfunction may confound the evaluation of neurologic and other adverse events).~* No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.~* No uncontrolled hypertension defined as systolic blood pressure \> 140 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management.~* No known active Hepatitis or HIV.~* No history of allergic reactions attributed to compounds sorafenib or its excipients.~* No uncontrolled intercurrent illness such as ongoing or active infection (fungal, bacterial, and/or viral), CTCAE grade 2 or greater.~* No thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.~* No serious non-healing wound, ulcer, or bone fracture.~* No major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.~* No condition that may impair the patient's ability to swallow whole pills.~* Patient must not have any malabsorption problem.~* Patients receiving St. John's Wort or rifampin (rifampicin) are ineligible.~* Patients with uncontrolled Autoimmune Hemolytic Anemia (AIHA) or autoimmune thrombocytopenia (ITP) are ineligible.~* Patients must not be experiencing psychiatric illness/social situations that would limit compliance with study requirements.~* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.~* Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from CLL except cervical cancer in-situ, treated basal cell carcinoma, squamous cell carcinoma of the skin, or superficial bladder tumor (Ta and Tis). Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before study entry are allowed. All cancer treatments must be completed at least 3 years prior to study entry (ie, signature date of the informed consent form).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Type: EXPERIMENTAL): Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).